Quick Answer
VERTEX PHARMACEUTICALS INC / MA reported Total Revenue of $12.00 billion for fiscal year 2025.
VERTEX PHARMACEUTICALS INC / MA — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $12.00B +8.9% |
$11.02B +11.7% |
$9.87B +10.5% |
$8.93B +17.9% |
$7.57B +22.1% |
$6.21B +49.1% |
| Revenue (ASC 606) | $12.00B +8.9% |
$11.02B +11.7% |
$9.87B +10.5% |
$8.93B +17.9% |
$7.57B +22.1% |
$6.21B +49.1% |
| Net Income | $3.95B +838.1% |
-$535.60M -114.8% |
$3.62B +9.0% |
$3.32B +41.8% |
$2.34B -13.6% |
$2.71B +130.4% |
| Diluted EPS | $15.32 +836.5% |
-$2.08 -115.0% |
$13.89 +8.3% |
$12.82 +42.3% |
$9.01 -12.4% |
$10.29 +128.2% |
| Total Assets | $25.64B +13.8% |
$22.53B -0.9% |
$22.73B +25.2% |
$18.15B +35.1% |
$13.43B +14.3% |
$11.75B +41.3% |
| Cash and Equivalents | $5.08B +11.3% |
$4.57B -55.9% |
$10.37B -1.3% |
$10.50B +54.6% |
$6.79B +13.5% |
$5.99B +92.6% |
| Stockholders Equity | $18.67B +13.7% |
$16.41B -6.7% |
$17.58B +26.4% |
$13.91B +37.7% |
$10.10B +16.3% |
$8.69B +42.8% |
| R&D Expense | — | — | — | — | $3.05B +66.8% |
$1.83B +4.3% |
| Operating Income | $4.17B +1891.9% |
-$232.90M -106.1% |
$3.83B -11.0% |
$4.31B +54.8% |
$2.78B -2.6% |
$2.86B +138.5% |
| Shares Outstanding | 253.99M -1.1% |
256.94M -0.3% |
257.70M +0.3% |
257.01M +1.0% |
254.48M -2.1% |
259.89M +0.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $3.08B | +11.0% | +3.8% |
| Revenue (ASC 606) | September 30, 2025 | $3.08B | +11.0% | +3.8% |
| Net Income | September 30, 2025 | $1.08B | +3.6% | +4.8% |
| Diluted EPS | September 30, 2025 | $4.20 | +4.7% | +5.3% |
| Total Assets | September 30, 2025 | $24.86B | +11.8% | +3.4% |
| Cash and Equivalents | September 30, 2025 | $4.94B | -5.7% | -0.7% |
| Stockholders Equity | September 30, 2025 | $17.32B | +10.8% | +0.8% |
| R&D Expense | March 31, 2022 | $603.10M | +32.3% | +22.1% |
| Operating Income | September 30, 2025 | $1.19B | +6.3% | +3.0% |
| Shares Outstanding | September 30, 2025 | 253.95M | -1.5% | -0.9% |
- VERTEX PHARMACEUTICALS INC / MA reported Total Revenue of $12.00 billion for fiscal year 2025.
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +8.9% in Total Revenue compared to the prior fiscal year.
- VERTEX PHARMACEUTICALS INC / MA reported Revenue (ASC 606) of $12.00 billion for fiscal year 2025.
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +8.9% in Revenue (ASC 606) compared to the prior fiscal year.
- VERTEX PHARMACEUTICALS INC / MA reported Net Income of $3.95 billion for fiscal year 2025.
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +838.1% in Net Income compared to the prior fiscal year.
- VERTEX PHARMACEUTICALS INC / MA reported Diluted EPS of $15.32 per share for fiscal year 2025.
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +836.5% in Diluted EPS compared to the prior fiscal year.
- VERTEX PHARMACEUTICALS INC / MA reported Total Assets of $25.64 billion for fiscal year 2025.
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +13.8% in Total Assets compared to the prior fiscal year.
- VERTEX PHARMACEUTICALS INC / MA reported Cash and Equivalents of $5.08 billion for fiscal year 2025.
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +11.3% in Cash and Equivalents compared to the prior fiscal year.
- VERTEX PHARMACEUTICALS INC / MA reported Stockholders Equity of $18.67 billion for fiscal year 2025.
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +13.7% in Stockholders Equity compared to the prior fiscal year.
- VERTEX PHARMACEUTICALS INC / MA reported R&D Expense of $3.05 billion for fiscal year 2021.
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +66.8% in R&D Expense compared to the prior fiscal year.
- VERTEX PHARMACEUTICALS INC / MA reported Operating Income of $4.17 billion for fiscal year 2025.
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +1891.9% in Operating Income compared to the prior fiscal year.
- VERTEX PHARMACEUTICALS INC / MA reported Shares Outstanding of 253.99 million shares for fiscal year 2025.
- VERTEX PHARMACEUTICALS INC / MA showed a decrease of -1.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: